The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease

O Hansson, RM Edelmayer, AL Boxer… - Alzheimer's & …, 2022‏ - Wiley Online Library
Blood‐based markers (BBMs) have recently shown promise to revolutionize the diagnostic
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …

Alzheimer's disease

P Scheltens, B De Strooper, M Kivipelto, H Holstege… - The Lancet, 2021‏ - thelancet.com
In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …

Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias

G Chételat, J Arbizu, H Barthel, V Garibotto… - The Lancet …, 2020‏ - thelancet.com
Various biomarkers are available to support the diagnosis of neurodegenerative diseases in
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …

Biomarkers for Alzheimer's disease: current status and prospects for the future

K Blennow, H Zetterberg - Journal of internal medicine, 2018‏ - Wiley Online Library
Accumulating data from the clinical research support that the core Alzheimer's disease (AD)
cerebrospinal fluid (CSF) biomarkers amyloid‐β (Aβ42), total tau (T‐tau), and …

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease

O Hansson, S Lehmann, M Otto, H Zetterberg… - Alzheimer's research & …, 2019‏ - Springer
The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ 42), total
Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau 181) have proven diagnostic …

High performance plasma amyloid-β biomarkers for Alzheimer's disease

A Nakamura, N Kaneko, VL Villemagne, T Kato… - Nature, 2018‏ - nature.com
To facilitate clinical trials of disease-modifying therapies for Alzheimer's disease, which are
expected to be most efficacious at the earliest and mildest stages of the disease,, supportive …

Performance of fully automated plasma assays as screening tests for Alzheimer disease–related β-amyloid status

S Palmqvist, S Janelidze, E Stomrud… - JAMA …, 2019‏ - jamanetwork.com
Importance Accurate blood-based biomarkers for Alzheimer disease (AD) might improve the
diagnostic accuracy in primary care, referrals to memory clinics, and screenings for AD trials …

Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: results from the Standardization of …

IMW Verberk, EO Misdorp, J Koelewijn… - Alzheimer's & …, 2022‏ - Wiley Online Library
Introduction Pre‐analytical sample handling might affect the results of Alzheimer's disease
blood‐based biomarkers. We empirically tested variations of common blood collection and …

Alzheimer's disease

P Scheltens, K Blennow, MMB Breteler, B De Strooper… - The Lancet, 2016‏ - thelancet.com
Although the prevalence of dementia continues to increase worldwide, incidence in the
western world might have decreased as a result of better vascular care and improved brain …

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

B Olsson, R Lautner, U Andreasson, A Öhrfelt… - The Lancet …, 2016‏ - thelancet.com
Background Alzheimer's disease biomarkers are important for early diagnosis in routine
clinical practice and research. Three core CSF biomarkers for the diagnosis of Alzheimer's …